{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:42:39Z","timestamp":1794008559717,"version":"4.8.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>DNA replication stress (RS), a prevalent feature of various malignancies, arises from both genetic mutations and genotoxic exposure. Elevated RS levels increase the vulnerability of cancer cells to ataxia telangiectasia and Rad3-related kinase inhibitors (ATRis). Here, we screened for DNA damage response inhibitors that enhance ATRi-induced cytotoxicity using SWI\/SNF complex-deficient cells and identified a potent synergy between ATRi and poly(ADP-ribose) polymerase inhibitor (PARPi), particularly in SMARCA4-deficient cells. PARP inhibition triggers chromatin changes, namely elevated histone H3 at lysine 9 di-methylation (H3K9me2), a hallmark of facultative heterochromatin, increasing dependence on ATR activity for replication fork progression and cell survival. Interestingly, SMARCA4 deficient cells, intrinsically vulnerable to replication stress, exhibited exacerbated DNA damage upon combined ATRi and PARPi treatment in a Mre11- and Mus81-mediated manner. In vivo, combined treatment with intermittent ATRi and continuous PARPi showed greater inhibition of tumor growth than ATRi alone in SMARCA4-deficient lung adenocarcinoma xenograft models. These findings demonstrate that PARPi-induced heterochromatin amplifies RS and ATRi susceptibility, providing a potential rationale for therapeutic strategies targeting SMARCA4-deficient tumors.<\/jats:p>","DOI":"10.1038\/s41420-025-02306-1","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T19:52:30Z","timestamp":1738093950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells"],"prefix":"10.1038","volume":"11","author":[{"given":"Kimiyoshi","family":"Yano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syoju","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoga","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5371-706X","authenticated-orcid":false,"given":"Takashi","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Dahmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank T.","family":"Zenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3583-4318","authenticated-orcid":false,"given":"Bunsyo","family":"Shiotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"2306_CR1","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol. 2017;18:622\u201336. https:\/\/doi.org\/10.1038\/nrm.2017.67.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2306_CR2","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.molcel.2022.05.004","volume":"82","author":"S Saxena","year":"2022","unstructured":"Saxena S, Zou L. Hallmarks of DNA replication stress. Mol Cell. 2022;82:2298\u2013314. https:\/\/doi.org\/10.1016\/j.molcel.2022.05.004.","journal-title":"Mol Cell"},{"key":"2306_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi NYL, Pilie PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA. Targeting ATR in patients with cancer. Nat Rev Clin Oncol. 2024;21:278\u201393. https:\/\/doi.org\/10.1038\/s41571-024-00863-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"2306_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrc3916","volume":"15","author":"H Gaillard","year":"2015","unstructured":"Gaillard H, Garcia-Muse T, Aguilera A. Replication stress and cancer. Nat Rev Cancer. 2015;15:276\u201389. https:\/\/doi.org\/10.1038\/nrc3916.","journal-title":"Nat Rev Cancer"},{"key":"2306_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","volume":"10","author":"M Macheret","year":"2015","unstructured":"Macheret M, Halazonetis TD. DNA replication stress as a hallmark of cancer. Annu Rev Pathol. 2015;10:425\u201348. https:\/\/doi.org\/10.1146\/annurev-pathol-012414-040424.","journal-title":"Annu Rev Pathol"},{"key":"2306_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1158\/2159-8290.CD-17-1461","volume":"8","author":"P Kotsantis","year":"2018","unstructured":"Kotsantis P, Petermann E, Boulton SJ. Mechanisms of oncogene-induced replication stress: jigsaw falling into place. Cancer Discov. 2018;8:537\u201355. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1461.","journal-title":"Cancer Discov"},{"key":"2306_CR7","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1101\/gad.214080.113","volume":"27","author":"FB Couch","year":"2013","unstructured":"Couch FB, Bansbach CE, Driscoll R, Luzwick JW, Glick GG, Betous R, et al. ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes Dev. 2013;27:1610\u201323. https:\/\/doi.org\/10.1101\/gad.214080.113.","journal-title":"Genes Dev"},{"key":"2306_CR8","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1016\/j.molcel.2021.05.027","volume":"81","author":"S Hambarde","year":"2021","unstructured":"Hambarde S, Tsai CL, Pandita RK, Bacolla A, Maitra A, Charaka V, et al. EXO5-DNA structure and BLM interactions direct DNA resection critical for ATR-dependent replication restart. Mol Cell. 2021;81:2989\u20133006.e2989. https:\/\/doi.org\/10.1016\/j.molcel.2021.05.027.","journal-title":"Mol Cell"},{"key":"2306_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.molcel.2019.10.008","volume":"77","author":"A Quinet","year":"2020","unstructured":"Quinet A, Tirman S, Jackson J, Svikovic S, Lemacon D, Carvajal-Maldonado D, et al. PRIMPOL-mediated adaptive response suppresses replication fork reversal in BRCA-deficient cells. Mol Cell. 2020;77:461\u201374.e469. https:\/\/doi.org\/10.1016\/j.molcel.2019.10.008.","journal-title":"Mol Cell"},{"key":"2306_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1083\/jcb.201404111","volume":"206","author":"AK Murphy","year":"2014","unstructured":"Murphy AK, Fitzgerald M, Ro T, Kim JH, Rabinowitsch AI, Chowdhury D, et al. Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery. J Cell Biol. 2014;206:493\u2013507. https:\/\/doi.org\/10.1083\/jcb.201404111.","journal-title":"J Cell Biol"},{"key":"2306_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.celrep.2019.09.008","volume":"29","author":"S Saxena","year":"2019","unstructured":"Saxena S, Dixit S, Somyajit K, Nagaraju G. ATR signaling uncouples the Role of RAD51 paralogs in homologous recombination and replication stress response. Cell Rep. 2019;29:551\u20139.e554. https:\/\/doi.org\/10.1016\/j.celrep.2019.09.008.","journal-title":"Cell Rep"},{"key":"2306_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1101\/gad.290957.116","volume":"31","author":"SA Yazinski","year":"2017","unstructured":"Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017;31:318\u201332. https:\/\/doi.org\/10.1101\/gad.290957.116.","journal-title":"Genes Dev"},{"key":"2306_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.molcel.2020.08.018","volume":"80","author":"JJ Kim","year":"2020","unstructured":"Kim JJ, Lee SY, Choi JH, Woo HG, Xhemalce B, Miller KM. PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells. Mol Cell. 2020;80:327\u201344.e328. https:\/\/doi.org\/10.1016\/j.molcel.2020.08.018.","journal-title":"Mol Cell"},{"key":"2306_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40578-2","volume":"14","author":"T Igarashi","year":"2023","unstructured":"Igarashi T, Mazevet M, Yasuhara T, Yano K, Mochizuki A, Nishino M, et al. An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress. Nat Commun. 2023;14:4991 https:\/\/doi.org\/10.1038\/s41467-023-40578-2.","journal-title":"Nat Commun"},{"key":"2306_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","volume":"155","author":"LI Toledo","year":"2013","unstructured":"Toledo LI, Altmeyer M, Rask MB, Lukas C, Larsen DH, Povlsen LK, et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell. 2013;155:1088\u2013103. https:\/\/doi.org\/10.1016\/j.cell.2013.10.043.","journal-title":"Cell"},{"key":"2306_CR16","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.aap9346","volume":"361","author":"JC Saldivar","year":"2018","unstructured":"Saldivar JC, Hamperl S, Bocek MJ, Chung M, Bass TE, Cisneros-Soberanis F, et al. An intrinsic S\/G(2) checkpoint enforced by ATR. Science. 2018;361:806\u201310. https:\/\/doi.org\/10.1126\/science.aap9346.","journal-title":"Science"},{"key":"2306_CR17","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","volume":"18","author":"E Lecona","year":"2018","unstructured":"Lecona E, Fernandez-Capetillo O. Targeting ATR in cancer. Nat Rev Cancer. 2018;18:586\u201395. https:\/\/doi.org\/10.1038\/s41568-018-0034-3.","journal-title":"Nat Rev Cancer"},{"key":"2306_CR18","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1111\/cas.15845","volume":"114","author":"K Yano","year":"2023","unstructured":"Yano K, Shiotani B. Emerging strategies for cancer therapy by ATR inhibitors. Cancer Sci. 2023;114:2709\u201321. https:\/\/doi.org\/10.1111\/cas.15845.","journal-title":"Cancer Sci"},{"key":"2306_CR19","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.tig.2020.07.011","volume":"36","author":"RC Centore","year":"2020","unstructured":"Centore RC, Sandoval GJ, Soares LMM, Kadoch C, Chan HM. Mammalian SWI\/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies. Trends Genet. 2020;36:936\u201350. https:\/\/doi.org\/10.1016\/j.tig.2020.07.011.","journal-title":"Trends Genet"},{"key":"2306_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","volume":"17","author":"P Mittal","year":"2020","unstructured":"Mittal P, Roberts CWM. The SWI\/SNF complex in cancer - biology, biomarkers and therapy. Nat Rev Clin Oncol. 2020;17:435\u201348. https:\/\/doi.org\/10.1038\/s41571-020-0357-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"2306_CR21","doi-asserted-by":"publisher","first-page":"zcaa005","DOI":"10.1093\/narcan\/zcaa005","volume":"2","author":"K Kurashima","year":"2020","unstructured":"Kurashima K, Kashiwagi H, Shimomura I, Suzuki A, Takeshita F, Mazevet M, et al. SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma. NAR Cancer. 2020;2:zcaa005 https:\/\/doi.org\/10.1093\/narcan\/zcaa005.","journal-title":"NAR Cancer"},{"key":"2306_CR22","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1158\/0008-5472.CAN-20-1744","volume":"80","author":"M Gupta","year":"2020","unstructured":"Gupta M, Concepcion CP, Fahey CG, Keshishian H, Bhutkar A, Brainson CF, et al. BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. Cancer Res. 2020;80:3841\u201354. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1744.","journal-title":"Cancer Res"},{"key":"2306_CR23","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/s41588-021-00867-2","volume":"53","author":"A Bayona-Feliu","year":"2021","unstructured":"Bayona-Feliu A, Barroso S, Munoz S, Aguilera A. The SWI\/SNF chromatin remodeling complex helps resolve R-loop-mediated transcription-replication conflicts. Nat Genet. 2021;53:1050\u201363. https:\/\/doi.org\/10.1038\/s41588-021-00867-2.","journal-title":"Nat Genet"},{"key":"2306_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13837","volume":"7","author":"CT Williamson","year":"2016","unstructured":"Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7:13837 https:\/\/doi.org\/10.1038\/ncomms13837.","journal-title":"Nat Commun"},{"key":"2306_CR25","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1158\/0008-5472.CAN-21-0628","volume":"81","author":"RM Chabanon","year":"2021","unstructured":"Chabanon RM, Morel D, Eychenne T, Colmet-Daage L, Bajrami I, Dorvault N, et al. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer Res. 2021;81:2888\u2013902. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-0628.","journal-title":"Cancer Res"},{"key":"2306_CR26","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1038\/s41388-018-0606-4","volume":"38","author":"C Wang","year":"2019","unstructured":"Wang C, Wang G, Feng X, Shepherd P, Zhang J, Tang M, et al. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. Oncogene. 2019;38:2451\u201363. https:\/\/doi.org\/10.1038\/s41388-018-0606-4.","journal-title":"Oncogene"},{"key":"2306_CR27","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/0008-5472.CAN-13-3229","volume":"74","author":"KN Mohni","year":"2014","unstructured":"Mohni KN, Kavanaugh GM, Cortez D. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer Res. 2014;74:2835\u201345. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3229.","journal-title":"Cancer Res"},{"key":"2306_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610\u201321. https:\/\/doi.org\/10.1038\/nrm.2017.53.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2306_CR29","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012;72:5588\u201399. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2753.","journal-title":"Cancer Res"},{"key":"2306_CR30","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim H, George E, Ragland R, Rafail S, Zhang R, Krepler C, et al. Targeting the ATR\/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models. Clin Cancer Res. 2017;23:3097\u2013108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2273.","journal-title":"Clin Cancer Res"},{"key":"2306_CR31","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","volume":"39","author":"RL Lloyd","year":"2020","unstructured":"Lloyd RL, Wijnhoven PWG, Ramos-Montoya A, Wilson Z, Illuzzi G, Falenta K, et al. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 2020;39:4869\u201383. https:\/\/doi.org\/10.1038\/s41388-020-1328-y.","journal-title":"Oncogene"},{"key":"2306_CR32","doi-asserted-by":"publisher","first-page":"112792","DOI":"10.1016\/j.celrep.2023.112792","volume":"42","author":"W Leung","year":"2023","unstructured":"Leung W, Simoneau A, Saxena S, Jackson J, Patel PS, Limbu M, et al. ATR protects ongoing and newly assembled DNA replication forks through distinct mechanisms. Cell Rep. 2023;42:112792 https:\/\/doi.org\/10.1016\/j.celrep.2023.112792.","journal-title":"Cell Rep"},{"key":"2306_CR33","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell. 2017;66:801\u201317. https:\/\/doi.org\/10.1016\/j.molcel.2017.05.015.","journal-title":"Mol Cell"},{"key":"2306_CR34","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011;7:428\u201330. https:\/\/doi.org\/10.1038\/nchembio.573.","journal-title":"Nat Chem Biol"},{"key":"2306_CR35","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","volume":"80","author":"S Rafiei","year":"2020","unstructured":"Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J, et al. ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer. Cancer Res. 2020;80:2094\u2013100. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3126.","journal-title":"Cancer Res"},{"key":"2306_CR36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1541-7786.MCR-14-0240","volume":"13","author":"DL Menezes","year":"2015","unstructured":"Menezes DL, Holt J, Tang Y, Feng J, Barsanti P, Pan Y, et al. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function. Mol Cancer Res. 2015;13:120\u20139. https:\/\/doi.org\/10.1158\/1541-7786.MCR-14-0240.","journal-title":"Mol Cancer Res"},{"key":"2306_CR37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","volume":"16","author":"A Min","year":"2017","unstructured":"Min A, Im SA, Jang H, Kim S, Lee M, Kim DK, et al. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. Mol Cancer Ther. 2017;16:566\u201377. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0378.","journal-title":"Mol Cancer Ther"},{"key":"2306_CR38","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","volume":"77","author":"A Schmitt","year":"2017","unstructured":"Schmitt A, Knittel G, Welcker D, Yang TP, George J, Nowak M, et al. ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma. Cancer Res. 2017;77:3040\u201356. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3398.","journal-title":"Cancer Res"},{"key":"2306_CR39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fonc.2018.00245","volume":"8","author":"H Hafsi","year":"2018","unstructured":"Hafsi H, Dillon MT, Barker HE, Kyula JN, Schick U, Paget JT, et al. Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status. Front Oncol. 2018;8:245 https:\/\/doi.org\/10.3389\/fonc.2018.00245.","journal-title":"Front Oncol"},{"key":"2306_CR40","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets. Genom Proteom Bioinform. 2022;20:587\u201396. https:\/\/doi.org\/10.1016\/j.gpb.2022.01.004.","journal-title":"Genom Proteom Bioinform"},{"key":"2306_CR41","doi-asserted-by":"publisher","unstructured":"Yap TA, Tolcher AW, Plummer R, Mukker JK, Enderlin M, Hicking C et al. First-in-human study of the ataxia telangiectasia and Rad3-related (ATR) Inhibitor Tuvusertib (M1774) as monotherapy in patients with solid tumors. Clin Cancer Res 2024. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-2409.","DOI":"10.1158\/1078-0432.Ccr-23-2409"},{"key":"2306_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00280-017-3455-x","volume":"81","author":"L van Andel","year":"2018","unstructured":"van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, et al. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients. Cancer Chemother Pharmacol. 2018;81:39\u201346. https:\/\/doi.org\/10.1007\/s00280-017-3455-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2306_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01401-x","volume":"8","author":"T Moiseeva","year":"2017","unstructured":"Moiseeva T, Hood B, Schamus S, O\u2019Connor MJ, Conrads TP, Bakkenist CJ. ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1. Nat Commun. 2017;8:1392 https:\/\/doi.org\/10.1038\/s41467-017-01401-x.","journal-title":"Nat Commun"},{"key":"2306_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","volume":"559","author":"A Maya-Mendoza","year":"2018","unstructured":"Maya-Mendoza A, Moudry P, Merchut-Maya JM, Lee M, Strauss R, Bartek J. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018;559:279\u201384. https:\/\/doi.org\/10.1038\/s41586-018-0261-5.","journal-title":"Nature"},{"key":"2306_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51667-1","volume":"15","author":"Z Machacova","year":"2024","unstructured":"Machacova Z, Chroma K, Lukac D, Protivankova I, Moudry P. DNA polymerase alpha-primase facilitates PARP inhibitor-induced fork acceleration and protects BRCA1-deficient cells against ssDNA gaps. Nat Commun. 2024;15:7375 https:\/\/doi.org\/10.1038\/s41467-024-51667-1.","journal-title":"Nat Commun"},{"key":"2306_CR46","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.molcel.2020.12.010","volume":"81","author":"MM Genois","year":"2021","unstructured":"Genois MM, Gagne JP, Yasuhara T, Jackson J, Saxena S, Langelier MF, et al. CARM1 regulates replication fork speed and stress response by stimulating PARP1. Mol Cell. 2021;81:784\u2013800.e788. https:\/\/doi.org\/10.1016\/j.molcel.2020.12.010.","journal-title":"Mol Cell"},{"key":"2306_CR47","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1101\/gad.348479.121","volume":"35","author":"A Simoneau","year":"2021","unstructured":"Simoneau A, Xiong R, Zou L. The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1\/2-deficient cells. Genes Dev. 2021;35:1271\u201389. https:\/\/doi.org\/10.1101\/gad.348479.121.","journal-title":"Genes Dev"},{"key":"2306_CR48","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.molcel.2023.05.026","volume":"83","author":"JM Schvartzman","year":"2023","unstructured":"Schvartzman JM, Forsyth G, Walch H, Chatila W, Taglialatela A, Lee BJ, et al. Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination. Mol Cell. 2023;83:2347\u201356.e2348. https:\/\/doi.org\/10.1016\/j.molcel.2023.05.026.","journal-title":"Mol Cell"},{"key":"2306_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcdb.2016.11.010","volume":"63","author":"F Ciccarone","year":"2017","unstructured":"Ciccarone F, Zampieri M, Caiafa P. PARP1 orchestrates epigenetic events setting up chromatin domains. Semin Cell Dev Biol. 2017;63:123\u201334. https:\/\/doi.org\/10.1016\/j.semcdb.2016.11.010.","journal-title":"Semin Cell Dev Biol"},{"key":"2306_CR50","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ng.3735","volume":"49","author":"BZ Stanton","year":"2017","unstructured":"Stanton BZ, Hodges C, Calarco JP, Braun SM, Ku WL, Kadoch C, et al. Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin. Nat Genet. 2017;49:282\u20138. https:\/\/doi.org\/10.1038\/ng.3735.","journal-title":"Nat Genet"},{"key":"2306_CR51","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/ncb2285","volume":"13","author":"L Ho","year":"2011","unstructured":"Ho L, Miller EL, Ronan JL, Ho WQ, Jothi R, Crabtree GR. esBAF facilitates pluripotency by conditioning the genome for LIF\/STAT3 signalling and by regulating polycomb function. Nat Cell Biol. 2011;13:903\u201313. https:\/\/doi.org\/10.1038\/ncb2285.","journal-title":"Nat Cell Biol"},{"key":"2306_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00644-y","volume":"8","author":"SMG Braun","year":"2017","unstructured":"Braun SMG, Kirkland JG, Chory EJ, Husmann D, Calarco JP, Crabtree GR. Rapid and reversible epigenome editing by endogenous chromatin regulators. Nat Commun. 2017;8:560 https:\/\/doi.org\/10.1038\/s41467-017-00644-y.","journal-title":"Nat Commun"},{"key":"2306_CR53","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.molcel.2019.10.010","volume":"77","author":"DA Matos","year":"2020","unstructured":"Matos DA, Zhang JM, Ouyang J, Nguyen HD, Genois MM, Zou L. ATR Protects the Genome against R Loops through a MUS81-Triggered Feedback Loop. Mol Cell. 2020;77:514\u201327.e514. https:\/\/doi.org\/10.1016\/j.molcel.2019.10.010.","journal-title":"Mol Cell"},{"key":"2306_CR54","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"A Ray Chaudhuri","year":"2016","unstructured":"Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535:382\u20137. https:\/\/doi.org\/10.1038\/nature18325.","journal-title":"Nature"},{"key":"2306_CR55","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.molcel.2017.07.001","volume":"67","author":"AM Kolinjivadi","year":"2017","unstructured":"Kolinjivadi AM, Sannino V, De Antoni A, Zadorozhny K, Kilkenny M, Techer H, et al. Smarcal1-mediated fork reversal triggers Mre11-dependent degradation of nascent DNA in the absence of Brca2 and stable Rad51 nucleofilaments. Mol Cell. 2017;67:867\u201381.e867. https:\/\/doi.org\/10.1016\/j.molcel.2017.07.001.","journal-title":"Mol Cell"},{"key":"2306_CR56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.molcel.2013.08.035","volume":"52","author":"HD Wyatt","year":"2013","unstructured":"Wyatt HD, Sarbajna S, Matos J, West SC. Coordinated actions of SLX1-SLX4 and MUS81-EME1 for Holliday junction resolution in human cells. Mol Cell. 2013;52:234\u201347. https:\/\/doi.org\/10.1016\/j.molcel.2013.08.035.","journal-title":"Mol Cell"},{"key":"2306_CR57","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.celrep.2015.12.093","volume":"14","author":"H Techer","year":"2016","unstructured":"Techer H, Koundrioukoff S, Carignon S, Wilhelm T, Millot GA, Lopez BS, et al. Signaling from Mus81-Eme2-Dependent DNA Damage Elicited by Chk1 Deficiency Modulates Replication Fork Speed and Origin Usage. Cell Rep. 2016;14:1114\u201327. https:\/\/doi.org\/10.1016\/j.celrep.2015.12.093.","journal-title":"Cell Rep"},{"key":"2306_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01180-5","volume":"8","author":"D Lemacon","year":"2017","unstructured":"Lemacon D, Jackson J, Quinet A, Brickner JR, Li S, Yazinski S, et al. MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells. Nat Commun. 2017;8:860 https:\/\/doi.org\/10.1038\/s41467-017-01180-5.","journal-title":"Nat Commun"},{"key":"2306_CR59","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0959-8049(16)32607-7","volume":"69","author":"TA Yap","year":"2016","unstructured":"Yap TA, Krebs MG, Postel-Vinay S, Bang YJ, El-Khoueiry A, Abida W, et al. Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers. Eur J Cancer. 2016;69:S2\u2013S2. https:\/\/doi.org\/10.1016\/S0959-8049(16)32607-7.","journal-title":"Eur J Cancer"},{"key":"2306_CR60","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","volume":"36","author":"A Thomas","year":"2018","unstructured":"Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee MJ, et al. Phase I Study of ATR Inhibitor M6620 in combination with topotecan in patients with advanced solid tumors. J Clin Oncol. 2018;36:1594\u2013602. https:\/\/doi.org\/10.1200\/JCO.2017.76.6915.","journal-title":"J Clin Oncol"},{"key":"2306_CR61","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","volume":"39","author":"A Thomas","year":"2021","unstructured":"Thomas A, Takahashi N, Rajapakse VN, Zhang X, Sun Y, Ceribelli M, et al. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell. 2021;39:566\u201379.e567. https:\/\/doi.org\/10.1016\/j.ccell.2021.02.014.","journal-title":"Cancer Cell"},{"key":"2306_CR62","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","volume":"27","author":"TA Yap","year":"2021","unstructured":"Yap TA, Krebs MG, Postel-Vinay S, El-Khouiery A, Soria JC, Lopez J, et al. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase i study. Clin Cancer Res. 2021;27:5213\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1032.","journal-title":"Clin Cancer Res"},{"key":"2306_CR63","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1158\/1078-0432.CCR-21-0251","volume":"27","author":"ST Kim","year":"2021","unstructured":"Kim ST, Smith SA, Mortimer P, Loembe AB, Cho H, Kim KM, et al. Phase I Study of Ceralasertib (AZD6738), a Novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer. Clin Cancer Res. 2021;27:4700\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0251.","journal-title":"Clin Cancer Res"},{"key":"2306_CR64","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/cas.12941","volume":"107","author":"M Saito","year":"2016","unstructured":"Saito M, Shiraishi K, Kunitoh H, Takenoshita S, Yokota J, Kohno T. Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci. 2016;107:713\u201320. https:\/\/doi.org\/10.1111\/cas.12941.","journal-title":"Cancer Sci"},{"key":"2306_CR65","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research, N.","year":"2014","unstructured":"Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543\u201350. https:\/\/doi.org\/10.1038\/nature13385.","journal-title":"Nature"},{"key":"2306_CR66","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/emboj.2010.27","volume":"29","author":"HS Lee","year":"2010","unstructured":"Lee HS, Park JH, Kim SJ, Kwon SJ, Kwon J. A cooperative activation loop among SWI\/SNF, gamma-H2AX and H3 acetylation for DNA double-strand break repair. EMBO J. 2010;29:1434\u201345. https:\/\/doi.org\/10.1038\/emboj.2010.27.","journal-title":"EMBO J"},{"key":"2306_CR67","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.dnarep.2015.04.023","volume":"32","author":"PM Brownlee","year":"2015","unstructured":"Brownlee PM, Meisenberg C, Downs JA. The SWI\/SNF chromatin remodelling complex: Its role in maintaining genome stability and preventing tumourigenesis. DNA Repair. 2015;32:127\u201333. https:\/\/doi.org\/10.1016\/j.dnarep.2015.04.023.","journal-title":"DNA Repair"},{"key":"2306_CR68","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature12146","volume":"497","author":"EC Dykhuizen","year":"2013","unstructured":"Dykhuizen EC, Hargreaves DC, Miller EL, Cui K, Korshunov A, Kool M, et al. BAF complexes facilitate decatenation of DNA by topoisomerase II\u03b1. Nature. 2013;497:624\u20137. https:\/\/doi.org\/10.1038\/nature12146.","journal-title":"Nature"},{"key":"2306_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10549","volume":"7","author":"A Husain","year":"2016","unstructured":"Husain A, Begum NA, Taniguchi T, Taniguchi H, Kobayashi M, Honjo T. Chromatin remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability. Nat Commun. 2016;7:10549 https:\/\/doi.org\/10.1038\/ncomms10549.","journal-title":"Nat Commun"},{"key":"2306_CR70","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/ng.3734","volume":"49","author":"C Kadoch","year":"2017","unstructured":"Kadoch C, Williams RT, Calarco JP, Miller EL, Weber CM, Braun SM, et al. Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states. Nat Genet. 2017;49:213\u201322. https:\/\/doi.org\/10.1038\/ng.3734.","journal-title":"Nat Genet"},{"key":"2306_CR71","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.1093\/nar\/gkq463","volume":"38","author":"S Messner","year":"2010","unstructured":"Messner S, Altmeyer M, Zhao H, Pozivil A, Roschitzki B, Gehrig P, et al. PARP1 ADP-ribosylates lysine residues of the core histone tails. Nucleic Acids Res. 2010;38:6350\u201362. https:\/\/doi.org\/10.1093\/nar\/gkq463.","journal-title":"Nucleic Acids Res"},{"key":"2306_CR72","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1073\/pnas.79.11.3423","volume":"79","author":"GG Poirier","year":"1982","unstructured":"Poirier GG, de Murcia G, Jongstra-Bilen J, Niedergang C, Mandel P. Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. Proc Natl Acad Sci USA. 1982;79:3423\u20137. https:\/\/doi.org\/10.1073\/pnas.79.11.3423.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2306_CR73","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1242\/jcs.109413","volume":"126","author":"G Smeenk","year":"2013","unstructured":"Smeenk G, Wiegant WW, Marteijn JA, Luijsterburg MS, Sroczynski N, Costelloe T, et al. Poly(ADP-ribosyl)ation links the chromatin remodeler SMARCA5\/SNF2H to RNF168-dependent DNA damage signaling. J Cell Sci. 2013;126:889\u2013903. https:\/\/doi.org\/10.1242\/jcs.109413.","journal-title":"J Cell Sci"},{"key":"2306_CR74","doi-asserted-by":"publisher","first-page":"13770","DOI":"10.1073\/pnas.0906920106","volume":"106","author":"AJ Gottschalk","year":"2009","unstructured":"Gottschalk AJ, Timinszky G, Kong SE, Jin J, Cai Y, Swanson SK, et al. Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler. Proc Natl Acad Sci USA. 2009;106:13770\u20134. https:\/\/doi.org\/10.1073\/pnas.0906920106.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2306_CR75","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1126\/science.1177321","volume":"325","author":"D Ahel","year":"2009","unstructured":"Ahel D, Horejsi Z, Wiechens N, Polo SE, Garcia-Wilson E, Ahel I, et al. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science. 2009;325:1240\u20133. https:\/\/doi.org\/10.1126\/science.1177321.","journal-title":"Science"},{"key":"2306_CR76","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/onc.2017.311","volume":"37","author":"H Yamaguchi","year":"2018","unstructured":"Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, et al. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene. 2018;37:208\u201317. https:\/\/doi.org\/10.1038\/onc.2017.311.","journal-title":"Oncogene"},{"key":"2306_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01034-4","volume":"13","author":"CS Tellez","year":"2021","unstructured":"Tellez CS, Picchi MA, Juri D, Do K, Desai DH, Amin SG, et al. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention. Clin Epigenetics. 2021;13:44 https:\/\/doi.org\/10.1186\/s13148-021-01034-4.","journal-title":"Clin Epigenetics"},{"key":"2306_CR78","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s41556-023-01167-z","volume":"25","author":"V Gaggioli","year":"2023","unstructured":"Gaggioli V, Lo CSY, Reveron-Gomez N, Jasencakova Z, Domenech H, Nguyen H, et al. Dynamic de novo heterochromatin assembly and disassembly at replication forks ensures fork stability. Nat Cell Biol. 2023;25:1017\u201332. https:\/\/doi.org\/10.1038\/s41556-023-01167-z.","journal-title":"Nat Cell Biol"},{"key":"2306_CR79","doi-asserted-by":"publisher","unstructured":"Petropoulos M, Karamichali A, Rossetti GG, Freudenmann A, Iacovino LG, Dionellis VS et al. Transcription-replication conflicts underlie sensitivity to PARP inhibitors. Nature 2024. https:\/\/doi.org\/10.1038\/s41586-024-07217-2.","DOI":"10.1038\/s41586-024-07217-2"},{"key":"2306_CR80","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.molcel.2018.06.004","volume":"71","author":"H Hanzlikova","year":"2018","unstructured":"Hanzlikova H, Kalasova I, Demin AA, Pennicott LE, Cihlarova Z, Caldecott KW. The Importance of Poly(ADP-Ribose) polymerase as a sensor of unligated Okazaki fragments during DNA replication. Mol Cell. 2018;71:319\u201331.e313. https:\/\/doi.org\/10.1016\/j.molcel.2018.06.004.","journal-title":"Mol Cell"},{"key":"2306_CR81","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nsmb.2501","volume":"20","author":"M Berti","year":"2013","unstructured":"Berti M, Ray Chaudhuri A, Thangavel S, Gomathinayagam S, Kenig S, Vujanovic M, et al. Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition. Nat Struct Mol Biol. 2013;20:347\u201354. https:\/\/doi.org\/10.1038\/nsmb.2501.","journal-title":"Nat Struct Mol Biol"},{"key":"2306_CR82","doi-asserted-by":"publisher","first-page":"eabm0314","DOI":"10.1126\/sciadv.abm0314","volume":"8","author":"KPM Mehta","year":"2022","unstructured":"Mehta KPM, Thada V, Zhao R, Krishnamoorthy A, Leser M, Lindsey Rose K, et al. CHK1 phosphorylates PRIMPOL to promote replication stress tolerance. Sci Adv. 2022;8:eabm0314 https:\/\/doi.org\/10.1126\/sciadv.abm0314.","journal-title":"Sci Adv"},{"key":"2306_CR83","doi-asserted-by":"publisher","unstructured":"Prado F. Non-recombinogenic functions of Rad51, BRCA2, and Rad52 in DNA damage tolerance. Genes 2021;12. https:\/\/doi.org\/10.3390\/genes12101550.","DOI":"10.3390\/genes12101550"},{"key":"2306_CR84","doi-asserted-by":"publisher","first-page":"7224","DOI":"10.1093\/nar\/gkab344","volume":"49","author":"T Thakar","year":"2021","unstructured":"Thakar T, Moldovan GL. The emerging determinants of replication fork stability. Nucleic Acids Res. 2021;49:7224\u201338. https:\/\/doi.org\/10.1093\/nar\/gkab344.","journal-title":"Nucleic Acids Res"},{"key":"2306_CR85","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s0092-8674(00)00030-1","volume":"102","author":"DA Bochar","year":"2000","unstructured":"Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS, et al. BRCA1 is associated with a human SWI\/SNF-related complex: linking chromatin remodeling to breast cancer. Cell. 2000;102:257\u201365. https:\/\/doi.org\/10.1016\/s0092-8674(00)00030-1.","journal-title":"Cell"},{"key":"2306_CR86","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1242\/jcs.159103","volume":"128","author":"W Qi","year":"2015","unstructured":"Qi W, Wang R, Chen H, Wang X, Xiao T, Boldogh I, et al. BRG1 promotes the repair of DNA double-strand breaks by facilitating the replacement of RPA with RAD51. J Cell Sci. 2015;128:317\u201330. https:\/\/doi.org\/10.1242\/jcs.159103.","journal-title":"J Cell Sci"},{"key":"2306_CR87","doi-asserted-by":"publisher","first-page":"671","DOI":"10.15252\/embr.201541455","volume":"17","author":"JK Ahlskog","year":"2016","unstructured":"Ahlskog JK, Larsen BD, Achanta K, Sorensen CS. ATM\/ATR-mediated phosphorylation of PALB2 promotes RAD51 function. EMBO Rep. 2016;17:671\u201381. https:\/\/doi.org\/10.15252\/embr.201541455.","journal-title":"EMBO Rep"},{"key":"2306_CR88","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1128\/MCB.01521-12","volume":"33","author":"K Somyajit","year":"2013","unstructured":"Somyajit K, Basavaraju S, Scully R, Nagaraju G. ATM- and ATR-mediated phosphorylation of XRCC3 regulates DNA double-strand break-induced checkpoint activation and repair. Mol Cell Biol. 2013;33:1830\u201344. https:\/\/doi.org\/10.1128\/MCB.01521-12.","journal-title":"Mol Cell Biol"},{"key":"2306_CR89","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1182\/blood-2012-07-441212","volume":"121","author":"Y Kim","year":"2013","unstructured":"Kim Y, Spitz GS, Veturi U, Lach FP, Auerbach AD, Smogorzewska A. Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. Blood. 2013;121:54\u201363. https:\/\/doi.org\/10.1182\/blood-2012-07-441212.","journal-title":"Blood"},{"key":"2306_CR90","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","volume":"163","author":"PD Shah","year":"2021","unstructured":"Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, et al. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol. 2021;163:246\u201353. https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.024.","journal-title":"Gynecol Oncol"},{"key":"2306_CR91","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1200\/PO.20.00439","volume":"5","author":"H Mahdi","year":"2021","unstructured":"Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, et al. Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (Olaparib Combinations). JCO Precis Oncol. 2021;5:1432\u201342. https:\/\/doi.org\/10.1200\/PO.20.00439.","journal-title":"JCO Precis Oncol"},{"key":"2306_CR92","doi-asserted-by":"publisher","first-page":"111081","DOI":"10.1016\/j.celrep.2022.111081","volume":"40","author":"M Zimmermann","year":"2022","unstructured":"Zimmermann M, Bernier C, Kaiser B, Fournier S, Li L, Desjardins J, et al. Guiding ATR and PARP inhibitor combinationswith chemogenomic screens. Cell Rep. 2022;40:111081 https:\/\/doi.org\/10.1016\/j.celrep.2022.111081.","journal-title":"Cell Rep"},{"key":"2306_CR93","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","volume":"27","author":"Z Tang","year":"2021","unstructured":"Tang Z, Pilie PG, Geng C, Manyam GC, Yang G, Park S, et al. ATR Inhibition Induces CDK1-SPOP signaling and enhances Anti-PD-L1 cytotoxicity in prostate cancer. Clin Cancer Res. 2021;27:4898\u2013909. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1010.","journal-title":"Clin Cancer Res"},{"key":"2306_CR94","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1158\/1078-0432.CCR-23-1003","volume":"29","author":"XD Liu","year":"2023","unstructured":"Liu XD, Zhang YT, McGrail DJ, Zhang X, Lam T, Hoang A, et al. SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma. Clin Cancer Res. 2023;29:4002\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1003.","journal-title":"Clin Cancer Res"},{"key":"2306_CR95","doi-asserted-by":"publisher","first-page":"e104036","DOI":"10.15252\/embj.2019104036","volume":"39","author":"X Feng","year":"2020","unstructured":"Feng X, Tubbs A, Zhang C, Tang M, Sridharan S, Wang C, et al. ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways. EMBO J. 2020;39:e104036 https:\/\/doi.org\/10.15252\/embj.2019104036.","journal-title":"EMBO J"},{"key":"2306_CR96","doi-asserted-by":"publisher","unstructured":"Vendetti FP, Pandya P, Clump DA, Schamus-Haynes S, Tavakoli M, diMayorca M. et al. The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. JCI Insight 8 (2023). https:\/\/doi.org\/10.1172\/jci.insight.165615.","DOI":"10.1172\/jci.insight.165615"},{"key":"2306_CR97","doi-asserted-by":"publisher","first-page":"8931","DOI":"10.1128\/JVI.78.16.8931-8934.2004","volume":"78","author":"M Kameoka","year":"2004","unstructured":"Kameoka M, Nukuzuma S, Itaya A, Tanaka Y, Ota K, Ikuta K, et al. RNA interference directed against Poly(ADP-Ribose) polymerase 1 efficiently suppresses human immunodeficiency virus type 1 replication in human cells. J Virol. 2004;78:8931\u20134. https:\/\/doi.org\/10.1128\/JVI.78.16.8931-8934.2004.","journal-title":"J Virol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02306-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02306-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02306-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T19:52:33Z","timestamp":1738093953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02306-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2306"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02306-1","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Astrid Zimmermann and Heike Dahmen are employees of the healthcare business of Merck KGaA, Darmstadt, Germany. Frank T. Zenke was an employee of the healthcare business of Merck KGaA, Darmstadt, Germany, at the time of the study. Bunsyo Shiotani received research grants from the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039\/100009945). The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods in this study were performed in accordance with relevant guidelines and regulations. Animal experiments were approved by the National Cancer Center Research Institute Committee for Ethics of Animal Experimentation (approval number: T21-011-M02). All procedures were conducted in accordance with institutional and national ethical guidelines for animal research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"31"}}